Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01216241 · ClinicalTrials.gov registry record · Phase 3
Daptomycin Versus Placebo in Patients With Neutropenia and Fever
A Phase 3 study, sponsored by University of Rochester.
- Terminated
- Registry status
- Phase 3
- Development phase
- 36
- Enrollment target
NCT01216241: Clinical Trial Phase 3 study, sponsored by University of Rochester.
NCT01216241 is a Phase 3 study that was terminated before completion, run by University of Rochester. The registered enrollment target is 36 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01216241, a Phase 3 study, was terminated before completion, sponsored by University of Rochester.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 36 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the benefits and side effects of daptomycin compared to placebo for the treatment of neutropenic fever.
Primary Outcome
To determine whether the percentage of neutropenic subjects that become afebrile by five days after fever first develops.
Interventions
- OTHER Saline Placebo
- DRUG Daptomycin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2011-04 |
| Est. Completion | 2013-04 |
| Phase | Phase 3 |
Why NCT01216241 stopped before completion
NCT01216241 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 2 interventions - of which Saline Placebo is the first listed.
NCT01216241 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01216241 about?
NCT01216241 is a clinical study titled "Daptomycin Versus Placebo in Patients With Neutropenia and Fever". The purpose of this study is to evaluate the benefits and side effects of daptomycin compared to placebo for the treatment of neutropenic fever.
What is the current status of trial NCT01216241?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 36 participants. The study started on 2011-04. Estimated completion is 2013-04.
What interventions are being tested in trial NCT01216241?
The interventions under investigation include: Saline Placebo (OTHER), Daptomycin (DRUG).
Who is sponsoring clinical trial NCT01216241?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01216241's enrollment target sits among peer trials
36 1901st of 2000 higher than 98 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia